Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What’s Next? Five Things To Look Out For In July

Viatris May Bag Landmark FDA Interchangeable Approvals

Executive Summary

In the month ahead, Viatris may land history-making FDA biosimilar approvals, while readers will enjoy Generics Bulletin’s usual close coverage of the quarterly financial reports.

You may also be interested in...

Cigna Infliximab Users Get $500 To Switch To Biosimilars

Program aims to share rebate savings from preferred drugs, ease treatment disruptions. Products like Remicade covered under medical benefits require new kinds of incentives for switching.

EU Industry Sets Out Priorities In Structured Dialog

As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.

Less Than Two Months Remain To Enter Global Generics & Biosimilars Awards 2021

With a looming entry deadline of 30 July, companies have a little under two months to enter the Global Generics & Biosimilars Awards 2021, ahead of the awards ceremony on 10 November.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts